DexCom Is Pricey For A Reason - Its Growth Story Reflects That

MarkHatfield/E+ via Getty Images Investment Thesis DexCom (NASDAQ:DXCM) is not exactly every investor’s cup of tea. The company operates in the medical technology space, which is far away from the hype in mainstream AI, and yet, the company’s stock often confounds investors with its high valuation metrics, per my observation. Rightly so, because 93x trailing twelve-month earnings or 80x forward earnings is often considered expensive. However, I believe investors fail to observe the robust growth DexCom  ...